LANTHEUS HOLDINGS, INC.
At today's price, LANTHEUS HOLDINGS, INC. (LNTH) is priced for +19.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Lantheus is a radiopharmaceuticals company whose engine is PYLARIFY, the leading prostate-cancer PET imaging agent, alongside DEFINITY for echocardiography and a growing neurology imaging line. • The decisive number is PYLARIFY's trajectory: its revenue fell 6.5% year over year to $240.9 million as the prostate-imaging market growth slowed and the agent's transitional reimbursement advantage expired, so the company's single largest product is shrinking [Source: Q1 FY2026 earnings release]. • W
Is LNTH overvalued? See what's priced in →
391 institutional managers reported holding LNTH in 13F filings for the quarter ended 2026-03-31. 60 opened new positions that quarter. Held by BlackRock, Vanguard Group, Farallon Capital, among others. On the short side, 6.1M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (7.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LNTH has cut its share count 4.1% over the past five years, spending $400.02M on repurchases. It pays no dividend. Cash returned over the past three years: $400.02M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at LNTH over the trailing three years. Absence is a fact about the company, not a signal. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LNTH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-05 | +14.0% | -12.4% |
| 2023-08-04 | -7.5% | -6.4% |
| 2023-11-03 | -2.7% | +0.3% |
| 2024-05-03 | +12.1% | +4.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LNTH's latest 8-K filings: 2026-05-07 (items 2.02, 9.01); 2026-05-01 (items 3.03, 5.02, 5.03, 5.07, 9.01); 2026-02-26 (items 2.02, 9.01); 2025-11-12 (items 5.02); 2025-11-06 (items 2.02, 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.